Atopic Dermatitis (AD) is a chronic skin condition marked by itching, erythema and skin barrier dysfunction, affecting millions globally and significantly impacting quality of life of patients. Current therapies, such as topical corticosteroids and calcineurin inhibitors, while effective, present safety concerns, especially with their prolonged use. The development of novel topical agents targeting specific inflammatory pathways has emerged as a promising approach for AD management, addressing both the efficacy and safety limitations of more established treatments. Among these new therapies, Phosphodiesterase-4 (PDE-4) inhibitors like crisaborole and roflumilast and Janus Kinase (JAK) inhibitors like ruxolitinib and delgocitinib show considerable efficacy and favourable safety profiles in reducing AD symptoms and improving skin barrier function. Additionally, innovative agents like tapinarof an Aryl hydrocarbon Receptor (AhR) modulator and asivatrep, a TRPV1 antagonist, demonstrate potential in improving AD symptoms with research also exploring the therapeutic role of skin microbiome modulation through topical probiotics. This research synthesizes findings from randomized controlled trials, meta-analyses and observational studies to evaluate the comparative effectiveness and safety of these newer topical agents with the aim of providing insights into optimal management strategies for mild-to-moderate AD in adults. Such evidence is crucial to guide clinical decision-making, improve patient outcomes and enhance therapeutic options in AD care.
Alexandre Abramavicus (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: